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ABSTRACT
Fifty stable mild bronchial asthma patients were studied to characterize the airway inflammation
using the technique of bronchoalveolar lavage (BAL). 18 normal non-smoking subjects were studied
as control subjects. Total inflammatory cells (29.6±18.4 x 106 /dl vs 16.0±6.6 x 106/dl, p(<0.001),
absolute macrophages (24.5±15.9 x 106/dl vs 13.3 ± 5.5 x 106/dl. p<0.001), eosinophils (1.0±1.5 x 106
dl vs 0.1±0.1 x 106/dl, p<0.001) and lymphocytes (3.8±4.2 x 106/dl vs 2.4±1.5 x 106/dl, p<0.05) were
significantly higher in BAL fluid from patients with bronchial asthma compared to normal control
subjects. Abnormally elevated eosinophils (>4%) and lymphocytes (>28%) in BAL fluid were seen in
15 (30%) and five (10%) patients respectively. This study demonstrates that chronic lung inflammation
characterised by abnormally elevated macrophages, eosinophils and lymphocytes persists even
in patients with stable mild bronchial asthma, despite medication with oral beta stimulants or
theophylline.
Introduction
Bronchial asthma is now considered an airway inflamma-
tory disorder characterised by reversible airway obstruction
and increased airway reactivity to both specific and non-
specific stimuli(1). Bronchoalveolar lavage (BAL) is useful
tool in the assessment of lower respiratorytract inflamma-
tion in various respiratory diseases including bronchial
asthma(2,3-6). BAL studies in bronchial asthma had shown
increased numbers of eosinophils and mast cells in the
airways (7-9). These ceils were in an activated state as
demonstrated by the presence of increased amounts of
mast ceil products(e.g., histamine) and eosinophil
products (e.g major basic protein) in the airways of asth-
matics compared to controls (8,10). There were also slough-
ing of airway epithelial cells (8,11). The immediate re-
sponse after exposure to allergen is mast cell degranulation
and the late response is characterised by an increase in
eosinophils, immature macrophages and T-cells (12,14).
There were only a few Indian studies that had analysed
brochoalveolar lavage cell profiles in bronchial asthma
(15.16). A study was therefore, planned to evaluate the
airway inflammatory process in stable bronchial asthma.
Materials and Methods
Fifty patients presenting with a history of intermittent
wheeze, chest tightness, cough and sputum production
were evaluated. Bronchial asthma had been previously
diagnosed in all of them by an independent physician.
Bronchial asthma was confirmed in these subjects by
pulmonary function tests which had shown reversibility to in
haled bronchodilators. The following criteria were adopted
for inclusion in the study as mild stable asthma:
1. No asthmatic symptoms, for at feast two weeks prior
to the study.
2. No steriods have been used. Only oral salbutamol and
oral theophylline had been used.
3. No cute asthma in the four weeks prior to study.
4. Chest radiograph normal.
5. FEV1 was equal to or above 60% of predicted and ratio
of FEV1/FVC was above 60%
A full size posterio-anterior chest radiograph was evaluated
in each subject. Other investigations included total and
differential leucocyte counts in peripheral blood. Informed
consent was obtained from each subject and the study was
approved by the institutional ethical committee.
Pulmonary function
Pulmonary function tests that included forcedvital capacity
(FVC) and forced expiatory volume in one second (FEV1)
were done on PK Morgan transfer test Model C (PK
Morgan, Chatham, UK). FVC and FEV1 were repeated after
an inhalation of 200 µg of salbutamol through a spacehaler.
Oral bronchodilators and theophylline were stopped 48
hours before pulmonary function tests. A response to the
administration of the bronchodilator aerosol was consid-
ered significant when the improvement in FEV1 and/or FVC
is both larger than 12% and exceeds 200ml (17).
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Bronchoalveolar lavage
Bronchoalveolar iavages were performed with a flexible
fibreoptic bronchoscope as previously described(18). The
lavages were done from right middle lobe and lingula. Five
20 ml aliquotes of normal saline solution at room tempera-
ture were instilled into each lobe and recovered immedi-
ately with the bronchoscope wedged in a subsegmental
bronchus. The fluid was pooled and filter preparations were
made for differential ceil count on lavage fluid and were
stained with hematoxylin-eosin (19). A minimum of 400
cells were counted for differential cell counts on each filter
preparation. The absolute number of different types of cells
were derived from total cells times differential percentages.
Eighteen non-smoking individuals were evaluated as con-
trol subjects. The mean age of normal subjects, was
25.2±8.6 yrs (range 15-53 yrs). None of them had respira-
tory symptoms or abnormal physical findings and all had
normal chest radiographs and normal pulmonary function
tests. None of the subjects were on any medication
If either lymphocytes (>28%) or eosinophils (>4%) are more
than two standard deviations above the normal mean,
these are classified as abnormal elevations.
The results are presented as mean±SD. All the mean
differences between groups were compared using Mann-
Whitney U test.
Results
There was 26 males and 24 females in the study. The mean
age of the 50 subjects was 23.9±7.2 years and the mean
weight was 48.2±9.4 kg. Two males were smokers. The
mean duration of symptoms was 7.3±5.7 years. All subjects
gave history of allergy to multiple allergens that included
dusts, certain food items. cold season, fumes etc. Family
history of bronchial asthma was present in 15 subjects. One
had a history of urticaria. All patients gave history of cough
and wheezing, and all were on medication with oral
bronchodilators (ß2 stimulants or theophylline) for control of
their asthma. None had received cromoglycate, Ketotifen
or antihistaminics in the past. Physical signs especially
rhonchi were heard in 21 subjects (42%). The mean total
leucocyte count in the peripheral blood was 9600±3151
cells per cumm, and the differential count was as follows:
neutrophils 51.9±11.6%, lymphocytes 37.2±9.5%, eosi-
nophils 10.8±7.7% and monocytes 0.1±0.2%. The mean
absolute eosinophil count in the peripheral blood was
1023±987 cells/cmm. The occupations of the study sub-
jects were as follows: factory workers (cement, tannery,
brass) (six), cooks(three), carpenters(two), drivers (two),
tailors (two), shopsalesman (one), police man (one), peon
in office(one). Eight subjects were students and 15 females
were housewives. Nine patients were unemployed. The
skiagrams chest were essentially normal except for in-
creased bronchovascular markings in some subjects.
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TABLE-1
Pulmonary function parameters in asthmatic subjects
Observed Predicted %Predicted
FVC(L) 2.87 2.92 98.2
±0.80 ±0.60 ±16.8
FEV1(L) 2.31 2.56 90.5
 ±0.70 ±0.60 ±19.4
FEV1/FVC% 80.3
+8.1
Pulmonary function results of the asthmatics are given in
Table 1. The mean pre-bronchodilator FVC (%predicted)
was 98±16.8% (range 64-139%) and FEV1 (%predicted)
was 90.5±19.4% (range 61-133%). The mean post
bronchodilator FVC (%predicted) was 104.0±13.7% (range
76-143%) and FEV1 (%predicted) was 98.7±17.1% (range
67-139%). The pre and post-bronchodilator FEV1/FVC%
were 80.3±8.1% and 82.8±8.3% respectively.
An analysis of the bronchoalveolar lavage fluid cells showed
the following results. The total inflammatory cells (29.6±18.4
x 106/dl vs 16.0±6.6 x 106/dl, p< .001), absolute macroph-
ages (24.5±15.9 x 106/dl vs 13.3±5.5 x 106/dl, p<0.001),
lymphocy es (3.8±4.2 x 106/dl vs 2.4±1.5 x 106/dl, p< .05)
an eosinophils (1.0±1.5 x 106/dl vs 0.1±0.1 x 106/dl, p
<.001) were significantly higher in bronchial asthma pa-
tients compared to normal subjects (Table2). The eosino-
phil percentage (3.1±2.7% vs 1.0±1.1%, p<0.001) was
also significantly higher in patients. Abnormal elevation of
osinophils (> 4%) and lymphocytes in BAL (> 28%) were
present in 15 (30%) and five (10%) asthmatics respectively.
TABLE- 2
Bronchoalveolar lavage results in controls and asthmatics
Control Bronchial asthma
(n=18) (n=50)   
Total cells 16.0±6.6 29.6±18.4 *
' x 106.dl
Macrophages % 83.7±6.3 82.8±13.0
" x 106.dl 13.3±5.5 24.5±15.9
Lymphocytes % 14.6±6.4 13.4±122
" x 106/dl               2.4±1.5 3.8±4.2 **
E sinphils % 1.0±1.1 3.1±2.7 *
" x 106/pl 0.1±0.1 1.0±1.5 *
Neutrophils % 0.7±0.8 0.6±2.1
" x 106.dl 0.1±0.1 0.3±1.4
% Recovery       60.2±6.9 68.2±8.8
p value * < 0.001 ** < 0.05
Discussion
This study demonstrates that there is an abnormal accumu-
ation of inflammatory cells as evidenced by significantly
high total cells in the lower respiratory tract of stable mild
bronchial asthma patients. This inflammation is
ch racterised by abnormally elevated macrophages, lym-
phocytes and eosinophils. All patients were asymptomatic
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atthetLneofstudyandhadonlymiMventi~torydefectand
were taking oral beta stimulants or theophylline. The
persistence of chronic inflammatory process in the lower
respiratory ract in these patients suggests that Oral
b&&od&tor therapy may not be suffiiient to suppress
the inflammation.
Autopsy studies from patients dyiig in status asthmaticus
had demonstrated mucus plugging of airways, goblet cell
hyperplasia, ubepithelial deposition of collagen, disrup-
tionof airway epithelium, s ooth muscle hypertrophy and
infiltration of airway walls by inflammatory cells (20-22).
Thus severe bronchial asthma is ss&ted with marked
airway inflammation. The demonstration of airway hyper-
responsivenessinmildasthrnapromptedseveraiinvestiga-
tors to put forth the hypothesis that airway inflammation is
present even when the disease is quiescent, and
broncholaveolarand endobronchial b opsy studies in indi-
viduals with mild asthma had shown evidence of airway
inflammation (11, 23-27). Based on these studies, the
expertpanelof the National Heart Lung and EQood I stitute
conclude&hat airway inflammation is present in virtually all
patientswi@asthma(28).Thus,thefindingof significantly
eleuated total cells in our study is in conformity with the
earlierobservationof airway inflammation in mild bronchial
asthma.
Although eosinophilic inflammatory process is the charac-
teristic feature of bronchial asthma, large numbers of
~,mphocytesand~rophageshadbeendemonstratedin
autopsyandbiipsy of ainvays in bronchialasthma patients
(%29,3O).T-cellinfittrates ina rways h db en foundto be
helper T cells which appear to be activated (25). Several
studies have suggesteda roleforT-cell deriied cytokines
in the initiation of eosinophilic inflammation (20,25).
tnterleu~-5(lL-5),granulocytemacrophage-colonystimu-
latingfactor (GM-CSF) and IL-3 causetissue localization,
prologation of survival, maturation and activation of eosi-
-%!s t!‘ladboasl s~e&‘w.mk*dTM; l&l
subsetof CD4+T-lymphocytesmight contribute oeo&o-
phi1 infittration (31). Antigen-specific IgE is required for
release of mast cell mediators in bronchialasthmaand IgE
production is dependent on lymphocytes(32,33,34). Alveo-
larmacrophages present allergen in the context of appro-
priate class II HLA antigens to helper T cells. Activated
!?e!per?ce!lscause an?lg n-specific B elfs to differentiate
into piasrna cells which produce IgE. In addition, it had
been demonstrated that lymphocytes produce i&mine
releasing factor (HRF) which facilitates tne rel ase of
histamine from mast- cells (35). T c&s also produce
chemotactic factors that attract eosinophils to the site of
disease(36). Inconformity withthesestudies,thedemon-
strationdabnormal~elevatedmacrop~,~phocytes
andeosi70philsin~hisstudyvalidatestheproposedmecha-
nism that several cell types are involved in the p thogen-
LUNGINDIA(1B95)XlIl,NOS.3&4(P.132-~~
esis of bronchial asthma. The absence of neutrophih
response in arthmatics requires further evaluation. its
sign-me is unknown.
In conclusion, this study demonstrates that chronic lu g
inflammation character&d by abnormally elevated rnac.
rophages, eosinophils and lymphocytes persists even h
patients~stablemildbronchialasthma,despitemed~
tion with oral beta stimulants or theophylline.
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